Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
ARS Pharmaceuticals, Inc. (SPRY) had Days Sales in Receivables of 113.73 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$22.68M |
|
$-60.62M |
|
$6.29M |
|
$16.39M |
|
$82.83M |
|
$-60.15M |
|
$-0.47M |
|
$-60.62M |
|
$-60.62M |
|
$-60.62M |
|
$-60.62M |
|
$-60.62M |
|
$-60.62M |
|
$-60.15M |
|
$-60.74M |
|
99.30M |
|
99.30M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$245.24M |
|
$2.29M |
|
$42.34M |
|
$287.57M |
|
$49.61M |
|
$171.19M |
|
$176.65M |
|
$226.26M |
|
$61.31M |
|
$47.13M |
|
$61.31M |
|
99.30M |
|
| Cash Flow Statement Financials | |
$-44.95M |
|
$27.79M |
|
$0.16M |
|
$41.32M |
|
$24.32M |
|
$-17.00M |
|
$7.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.94 |
|
-- |
|
-- |
|
0.74 |
|
2.79 |
|
72.29% |
|
-265.18% |
|
-265.18% |
|
-- |
|
-267.26% |
|
-267.26% |
|
$-44.95M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.71 |
|
0.79 |
|
|
Days Sales in Receivables |
113.73 |
-98.87% |
|
-128.61% |
|
-21.08% |
|
-26.07% |
|
$0.62 |
|
$-0.45 |
|
$-0.45 |
|